Pfizer COVID vaccine trial for children aged under 12 shows 'robust immune response'

Credit: Sky News- Published on September 20, 2021
A Pfizer-BioNTech COVID-19 vaccine trial for children aged between five and 11 has produced "positive results" and has shown a "robust immune response", the two firms have said.

Video credit: Wibbitz Top Stories
Published on September 20, 2021 -  01:30
Pfizer Says Trial Shows COVID-19 Vaccine Is Safe and Effective for 5 to 11 Year-Olds
Pfizer Says Trial Shows, COVID-19 Vaccine , Is Safe and Effective for 5 to 11 Year-Olds. On September 20, Pfizer said that a Phase 2/3 trial showed that its COVID-19 vaccine was safe and effective for children ages 5 to 11. CNN reports that these are the first such results released for this age group for a COVID-19 vaccine in the United States. CNN also points out that the data from the study has not yet been peer-reviewed or published. CNN also points out that the data from the study has not yet been peer-reviewed or published. According to the FDA, once the Pfizer data is submitted, the agency could authorize a vaccine for younger children in a matter of weeks. According to the FDA, once the Pfizer data is submitted, the agency could authorize a vaccine for younger children in a matter of weeks. The trial, which included 2,268 participants ages 5 to 11, used a two-dose regimen of the vaccine administered 21 days apart. The trial, which included 2,268 participants ages 5 to 11, used a two-dose regimen of the vaccine administered 21 days apart. A 10-microgram dose, smaller than the 30-microgram dose that has been used for those 12 and older, was administered in the trial. A 10-microgram dose, smaller than the 30-microgram dose that has been used for those 12 and older, was administered in the trial. The 10 microgram dose was carefully selected as the preferred dose for safety, tolerability and immunogenicity in children 5 to 11 years of age, Pfizer news release, via CNN. The 10 microgram dose was carefully selected as the preferred dose for safety, tolerability and immunogenicity in children 5 to 11 years of age, Pfizer news release, via CNN. Pfizer said the levels compared well with older people who received the larger dose, demonstrating a , "strong immune response in this cohort of children one month after the second dose.". Further, the COVID-19 vaccine was well tolerated, with side effects generally comparable to those observed in participants 16 to 25 years of age, Pfizer news release, via CNN. According to a spokesperson for Pfizer, the trial resulted in no instances of myocarditis, ... ... a type of heart inflammation that has been linked with mRNA vaccines

You are here


๐Ÿ’ก newsR Knowledge: Other News Mentions

COVID-19

Contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Active Covid cases in India dropped below 2 lakh on Saturday for the first time in 218 days since the early days of the second wave. A day after Dussehra and..
Credit: IndiaTimes - Published 5 hours ago

n the run-up to its efforts to reach the milestone of administering 100 crore Covid vaccine doses and to counter hestiancy, the central government on Saturday..
Credit: IndiaTimes - Published 5 hours ago

Robert Durst is starting out his life imprisonment on a hospital bed -- the guy has COVID-19, and is hooked up to a machine to help him survive ... so says his..
Credit: TMZ.com - Published 7 hours ago

US real estate heir Robert Durst has tested positive for COVID-19 and is on a ventilator in hospital - days after being sentenced to life in prison for murdering..
8 hours ago • Sky News



Related videos from verified sources

How the Rollouts of the Polio Vaccine and COVID-19 Vaccine Compare 01:30
Credit: Wibbitz Top Stories - Published 2 days ago 


COVID-19 vaccine ready for young children in a few weeks 02:27
Credit: NewsChannel 5 Nashville - Published 3 days ago 


Survey: Nearly a third of adults say they are very unlikely to get their children vaccinated for COVID-19 03:30
Credit: KTNV Channel 13 Las Vegas - Published 3 days ago 


You might like